Skip to content
Apraclonidine
Iopidine (apraclonidine) is a small molecule pharmaceutical. Apraclonidine was first approved as Iopidine on 1987-12-31. It is used to treat ocular hypertension in the USA. The pharmaceutical is active against alpha-2C adrenergic receptor and alpha-2A adrenergic receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
eye diseasesD005128
Trade Name
FDA
EMA
Iopidine (generic drugs available since 2009-03-12)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Apraclonidine hydrochloride
Tradename
Company
Number
Date
Products
IOPIDINEHarrowN-019779 RX1987-12-31
1 products, RLD, RS
IOPIDINEHarrowN-020258 RX1993-07-30
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
apraclonidine ophthalmicANDA2020-10-07
iopidine New Drug Application2020-10-01
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
ocular hypertensionEFO_1001069D009798H40.0
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01E: Antiglaucoma preparations and miotics
— S01EA: Sympathomimetics in glaucoma therapy
— S01EA03: Apraclonidine
HCPCS
No data
Clinical
Clinical Trials
43 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B20618511241
Cardiovascular diseasesD002318EFO_0000319I98———1—1
Hiv-associated lipodystrophy syndromeD039682EFO_1001348———1—1
HivD006678O98.7———1—1
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Acquired immunodeficiency syndromeD000163EFO_0000765B201————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameAPRACLONIDINE
INNapraclonidine
Description
Apraclonidine is an imidazoline that is 2-amino 4,5-dihydro-1H-imidazoline in which one of the exocyclic amino hydrogens has been replaced by a 4-amino-2,6-dichlorophenyl group. It has a role as an alpha-adrenergic agonist, an antiglaucoma drug, an ophthalmology drug, a beta-adrenergic agonist and a diagnostic agent. It is a member of imidazolines, a dichlorobenzene and a member of guanidines. It is a conjugate base of an apraclonidine(1+).
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Nc1cc(Cl)c(N=C2NCCN2)c(Cl)c1
Identifiers
PDB—
CAS-ID66711-21-5
RxCUI14845
ChEMBL IDCHEMBL647
ChEBI ID2788
PubChem CID2216
DrugBankDB00964
UNII ID843CEN85DI (ChemIDplus, GSRS)
Target
Agency Approved
ADRA2C
ADRA2C
ADRA2A
ADRA2A
Organism
Homo sapiens
Gene name
ADRA2C
Gene synonyms
ADRA2L2, ADRA2RL2
NCBI Gene ID
152
Protein name
alpha-2C adrenergic receptor
Protein synonyms
adrenergic, alpha-2C-, receptor, Alpha-2 adrenergic receptor subtype C4, Alpha-2C adrenoceptor, Alpha-2C adrenoreceptor, Alpha-2CAR, alpha2-AR-C4
Uniprot ID
Q9HB49
Mouse ortholog
Adra2c (11553)
alpha-2C adrenergic receptor (Q01337)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 610 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1,155 adverse events reported
View more details